Oscar Reig-Torras
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: November 06, 2025
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer.
Journal: The New England journal of medicine
Published: October 22, 2025
Pharmacokinetics and bioavailability of pembrolizumab with berahyaluronidase alfa for subcutaneous administration in participants with advanced or metastatic solid tumors: The phase 1 study 3475A-C18.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 14, 2025
Exercise in patients with metastatic prostate cancer: A comprehensive review.
Journal: Cancer treatment reviews
Published: June 24, 2025
Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study.
Journal: Clinical genitourinary cancer
Published: April 24, 2025
Expert consensus on patterns of progression in kidney cancer after adjuvant immunotherapy and subsequent treatment strategies.
Journal: Cancer treatment reviews
Published: January 30, 2025
Comparative genomics incorporating translocation renal cell carcinoma mouse model reveals molecular mechanisms of tumorigenesis.
Journal: The Journal of clinical investigation
Published: March 15, 2023
Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma.
Journal: European urology
Published: August 09, 2021
A renal cell carcinoma tumorgraft platform to advance precision medicine.
Journal: Cell reports
Published: June 17, 2021
HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 06, 2019
Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: August 16, 2015
Showing 1-11 of 11
Last Updated: 09/26/2026